"label","uuid:ID","name","id","rationale","description"
"","ec137ef9-be6c-4c3c-8b09-0fbe67101392","Study Design 1","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study"
